Parabilis Medicines, Inc. (PBLS) Investor Relations Documents

Parabilis Medicines, Inc. (PBLS) investor relations documents from the company's IR site: 2 presentations, 20 press releases; latest deck 2026-08-25. Read in-app with summaries. First-party data.

PDF Version: Parabilis Medicines has appointed Dr. Craig L. Tendler, a veteran oncology drug development leader formerly of Johnson & Johnson, to its Board of Directors.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-25PresentationPDF Version
2026-08-25Press releaseParabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
2026-08-13Press releaseParabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-12PresentationParabilis Corporate Presentation
2026-06-11Press releaseParabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Optio
2026-06-10Press releasePDF Version
2026-06-09Press releaseParabilis Medicines Announces Pricing of Upsized Initial Public Offering
2026-05-18Press releaseParabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™
2026-05-07Press releaseParabilis Medicines Appoints Biopharmaceutical Finance Leader Alan M. Sebulsky to Board of Directors
2026-04-14Press releaseParabilis Medicines Expands Executive Leadership Team
2026-03-11Press releaseParabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receive
2026-03-05Press releaseParabilis Medicines Reports Early Clinical Evidence that Zolucatetide Reduces Polyp Burden in a Patient with Familial Ad
2026-01-08Press releaseParabilis Medicines Announces Oversubscribed $305 Million Financing to Support Ongoing FOG-001 (zolucatetide) Clinical D
2025-11-12Press releasePDF Version
2024-01-04Press releasePDF Version
Press releaseParabilis Medicines™ – Formerly FogPharma – Announces New Company Name and Unveils AI- and Physics-Based Discovery Platf
Press releaseParabilis Medicines Reports Positive Proof-of-Mechanism Data for Groundbreaking ERG Degrader Program
Press releaseParabilis Medicines Presents Clinical Data Demonstrating First-Ever Drugging of Key Cancer Driver with FOG-001
Press releaseParabilis Medicines Presents Clinical and Preclinical Data Demonstrating Broad Potential of Helicon™ Peptides at AACR-NC
Press releaseParabilis Medicines to Present Overview of Ongoing Phase 1/2 Study of FOG-001, a β-cateninTCF4 Inhibitor, at Upcoming Me
Press releaseParabilis Medicines Appoints Fawzi Benzaghou, M.D., as Chief Medical Officer
Press releaseFogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies

PBLS overview · PBLS earnings · PBLS financials · PBLS KPIs · PBLS documents · PBLS ownership · PBLS peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.